22 February, 2017

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq: FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain. A link to Mike’s interview can be found below:

http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

HotSpot Therapeutics appoints Niti Goel, M.D., as Chief Medical Officer

Nitrase Therapeutics announces the appointment of three industry veterans to its Board of Directors

Mediar Therapeutics enters into a collaboration and option agreement with Ono Pharma to develop novel treatments for fibro-inflammatory diseases

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease

HAYA Therapeutics receives FDA Fast Track Designation for HTX-001

Moon Surgical and KARL STORZ Announce Strategic Commercial Collaboration to Advance Scalable Surgery